Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Frank possesses significant biotech and pharmaceutical experience, having been the president and chief executive officer of Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest Laboratories.
Caroline was honored in 2015 with the New Jersey Governor’s Jefferson Award for Public Service for her support of youth development in the state.
He became Intellia’s president and chief executive officer in January 2018.
Intellia and Regeneron expanded their collaboration in 2020, with Regeneron having an additional option to extend by two more years in the future, View Press Release
Before joining Intellia in July 2021, Ian served as senior vice president, Investor and Public Relations at Karyopharm Therapeutics, an oncology-focused pharmaceutical company.
In October 2021, Intellia and SparingVision announced a collaboration to develop novel genomic medicines utilizing CRISPR/Cas9Adapted from a naturally occurring bacterial immune system, CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats.
Rate Intellia Therapeutics' efforts to communicate its history to employees.
Do you work at Intellia Therapeutics?
Is Intellia Therapeutics' vision a big part of strategic planning?
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 621 |
| Regeneron | 1988 | $14.2B | 9,123 | 362 |
| Merck | 1891 | $64.2B | 74,000 | 1,849 |
| Seagen | 1997 | $2.0B | 900 | - |
| Nektar Therapeutics | 1990 | $98.4M | 718 | - |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 268 |
| Zoetis | 1952 | $9.3B | 11,300 | 242 |
| bluebird bio | 1992 | $3.7M | 518 | 13 |
| Sangamo Therapeutics | 1995 | $57.8M | 354 | 1 |
Zippia gives an in-depth look into the details of Intellia Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intellia Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Intellia Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Intellia Therapeutics. The data presented on this page does not represent the view of Intellia Therapeutics and its employees or that of Zippia.
Intellia Therapeutics may also be known as or be related to INTELLIA THERAPEUTICS INC., Intellia Therapeutics, Intellia Therapeutics Inc and Intellia Therapeutics, Inc.